GlassScriptPhysician profile
Charles Basil Ike
NPI 1366555799
$1,063.53
in general payments reported to CMS, 2019-2025
23 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.43 · 2022: $223 · 2023: $246 · 2024: $279 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $110.24 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Novo Nordisk INC | $92.02 | 2022-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $81.95 | 2022 | |
| Shield Therapeutics INC | $74.26 | 2023-2025 | Accrufer |
| Exact Sciences Corporation | $69.00 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $65.18 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $61.03 | 2024-2025 | M-M-R II, Gardasil 9, Proquad |
| Dynavax Technologies Corporation | $59.22 | 2023-2024 | Heplisav-B |
| Pfizer INC. | $52.40 | 2025 | |
| Gilead Sciences, INC. | $49.01 | 2023 | Epclusa |
| Lilly USA, LLC | $45.76 | 2022-2025 | Mounjaro, Zepbound |
| Amgen INC. | $44.89 | 2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $44.49 | 2022-2023 | Farxiga |
| Phadia US INC. | $37.43 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.39 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $23.96 | 2023 | |
| Abbott Laboratories | $23.20 | 2022 | |
| Cranial Technologies, INC | $18.62 | 2024 | Doc Band |
| Otsuka America Pharmaceutical, INC. | $18.40 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $18.39 | 2025 | Cobenfy |
| Verrica Pharmaceuticals INC. | $18.21 | 2024 | Ycanth |
| Dexcom, INC. | $14.73 | 2022 | |
| Organon LLC | $11.75 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Ike listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.